Trial
NCT02624700
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Virginia Commonwealth University
Collaborators
Eli Lilly and Company; Bayer
Condition
Breast Cancer
Intervention
Experimental Arm A: Pemetrexed
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-14